What is CStone Pharmaceuticals?
CStone Pharmaceuticals, a biopharmaceutical company, researches and develops anti-cancer therapies to address the unmet medical needs of cancer patients in Mainland China and internationally.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
CStone Pharmaceuticals, a biopharmaceutical company, researches and develops anti-cancer therapies to address the unmet medical needs of cancer patients in Mainland China and internationally. The company offers CEJEMLY (sugemalimab), a monoclonal antibody against programmed death (PD) ligand 1 for the treatment of non-small cell lung cancer (NSCLC), gastric adenocarcinoma/gastroesophageal junction adenocarcinoma, esophageal squamous cell carcinoma, and relapsed or refractory natural killer/T cell lymphoma; GAVRETO (pralsetinib), a RET inhibitor to treat patients with advanced or metastatic RET-mutant medullary and RET fusion-positive thyroid cancers, as well as NSCLC and multiple tumors; and AYVAKIT (avapritinib), a KIT/PDGFRA inhibitor for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumors harboring a PDGFRA exon 18 mutation, and systematic mastocytosis. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 1.22B.
A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.